Clinical review pending
Type 2 diabetes (ICD-10 E11) is a metabolic condition in which blood glucose remains elevated. In nonpregnant adults, diagnostic thresholds include A1C at least 6.5%, fasting plasma glucose at least 126 mg/dL, or a two-hour oral glucose tolerance result at least 200 mg/dL. A random plasma glucose at least 200 mg/dL with classic symptoms can establish the diagnosis. Without unequivocal symptomatic hyperglycemia, confirmation generally needs a second abnormal result. Prediabetes indicates increased risk, not inevitable progression; appropriate intervention can reduce that risk. Test choice and interpretation depend on the individual, and pregnancy uses a separate assessment. National estimates change over time and should not be treated as a prediction for an individual.
What type 2 diabetes is and how it is diagnosed
A1C, fasting plasma glucose and oral glucose tolerance testing can help diagnose diabetes. Without unequivocal symptomatic hyperglycemia, an abnormal result generally requires confirmation. A random plasma glucose at least 200 mg/dL with classic symptoms can establish the diagnosis without waiting for a repeat test. A1C can be unreliable in some blood disorders or pregnancy; test choice should account for that context. Prediabetes increases future risk and warrants an individualized prevention and reassessment plan. Ask what each test is intended to clarify and who will review its result.
Symptoms — often subtle until glucose is high
- Increased thirst and frequent urination, especially at night
- Unexplained weight loss or, less commonly, weight gain
- Fatigue that does not resolve with rest
- Blurred vision that fluctuates with glucose level
- Slow-healing cuts, recurrent yeast or urinary infections
- Tingling or numbness in hands and feet (later stages, peripheral neuropathy)
Diabetes Treatment Options to Discuss
Diabetes treatment addresses glucose alongside cardiovascular, kidney and other health risks. Medication choice depends on the whole clinical picture, tolerability, access and preferences, rather than a mandatory sequence for everyone. Heart or kidney conditions can affect which medicine is appropriate. Other glucose-lowering classes can be considered according to individual needs. Review risks, monitoring and the responsible prescriber before changing treatment.
- Tests to consider individually — A1C, fasting lipids, kidney function (eGFR + urine ACR), liver, and B12 when appropriate
- Discuss nutrition appropriate to individual food preferences, including Cuban or Latin-American patterns; confirm available support
- Discuss FDA-approved antidiabetic classes selected to your profile; confirm prescribing, monitoring and access arrangements
- Medication eligibility — discuss options and confirm prescribing, monitoring and access arrangements
- Insulin initiation and titration when needed; confirm the responsible prescriber and language support for teach-back
- Discuss annual diabetic eye and foot examinations; confirm the appropriate service, availability and result review
- If clinically appropriate, discuss outside CGM assessment; confirm receiving-service acceptance, access, cost and follow-up ownership
- When complexity warrants outside endocrinology, nephrology or cardiology, confirm acceptance, access, costs and interim responsibility
Pre-diabetes — the most important window
Prediabetes is a reason to discuss prevention and follow-up, not a prediction that every person will develop diabetes on a fixed timetable. Nutrition, suitable activity and weight support when relevant can reduce risk. Appropriate goals account for health conditions, starting function and access. Some higher-risk patients may discuss preventive medication. Confirm the actual resources available and how repeat testing will be reviewed; this page does not establish enrollment in a structured prevention program.
Hispanic and Latino adults face a higher diabetes burden
Diabetes risk and access to care vary within every population. Hispanic and Latino communities are diverse, so national averages should not determine an individual diagnosis or treatment plan. Discuss family history, prior results, food preferences, work demands and practical barriers without assuming a single dietary or genetic explanation. Ask which language and education resources are available for your visit.
Medication options and individual monitoring
Medication options, including GLP-1 receptor agonists when appropriate, require an individual assessment of indication, risks, access and monitoring. Discuss the responsible prescriber, necessary tests and follow-up before changing treatment. Availability of a dedicated medication program or authorization service is not established by this page.
Foot Care, Eye Exams and Complications to Discuss
A provider selects appropriate complication checks; these guideline considerations are not a clinic service bundle. Confirm the responsible examiner, outside testing or referral access, cost and result review.
- Annual dilated retinal exam — diabetic retinopathy is a leading cause of preventable blindness
- Annual comprehensive foot exam — monofilament testing for early peripheral neuropathy plus vascular check
- Yearly urine albumin-to-creatinine ratio and eGFR — diabetic kidney disease is silent and treatable when caught early
- Blood pressure control to ADA targets — typically <130/80 for most patients with diabetes
- Lipid management with class-based therapy when LDL or cardiovascular risk warrants it
- Smoking cessation, sleep apnea screening, and dental care referral as part of cardiometabolic care
Insurance, availability to be confirmed, and bilingual diabetes education in Doral
Confirm provider availability, test location, referrals, costs and insurance coverage before scheduling. Testing or specialist care may take place outside Viva; acceptance and timing require confirmation.
- Confirm provider availability, test location, referrals, costs and insurance coverage before scheduling. Testing or specialist care may take place outside Viva; acceptance and timing require confirmation.
- availability to be confirmed when symptoms or a glucose reading need quick attention
- Follow-up format — confirm whether an in-person or remote visit is available and clinically suitable
- Language support — confirm English or Spanish resources for the planned visit
- Referral planning — consider appropriate outside specialists; confirm acceptance, coverage and timing
Sources
- CDC — National Diabetes Statistics Report — Centers for Disease Control and Prevention
- NIH NIDDK — Diabetes Overview — National Institute of Diabetes and Digestive and Kidney Diseases (NIH)
- USPSTF — Prediabetes and Type 2 Diabetes: Screening (2021) — U.S. Preventive Services Task Force
- AAFP — Type 2 Diabetes Clinical Resources — American Academy of Family Physicians
- Diabetes tests and diagnosis — National Institute of Diabetes and Digestive and Kidney Diseases (NIH)
- Diabetes medicines and other treatments — National Institute of Diabetes and Digestive and Kidney Diseases (NIH)
Frequently Asked Questions
What is type 2 diabetes and how is it diagnosed?
A1C, fasting plasma glucose and oral glucose tolerance testing can help diagnose diabetes. Without unequivocal symptomatic hyperglycemia, an abnormal result generally requires confirmation. A random plasma glucose at least 200 mg/dL with classic symptoms can establish the diagnosis without waiting for a repeat test. A1C can be unreliable in some blood disorders or pregnancy; test choice should account for that context. Prediabetes increases future risk and warrants an individualized prevention and reassessment plan. Ask what each test is intended to clarify and who will review its result.
What is prediabetes and how can risk be reduced?
Prediabetes includes A1C 5.7–6.4% or fasting glucose 100–125 mg/dL in nonpregnant adults. Appropriate nutrition, activity and weight support can reduce progression risk. A plan should include individualized goals and repeat testing, with medication discussion for selected higher-risk patients.
What A1C target should I aim for?
The ADA standard general target is A1C < 7% for most non-pregnant adults with diabetes. Targets are individualized — tighter (around 6.5%) for younger patients with no complications, looser (7.5-8%) for older patients, those with severe comorbidities, or with high hypoglycemia risk. Your provider sets a target that fits your full picture and revisits it every 3-6 months.
How are diabetes treatment options selected?
Diabetes treatment addresses glucose alongside cardiovascular, kidney and other health risks. Medication choice depends on the whole clinical picture, tolerability, access and preferences, rather than a mandatory sequence for everyone. Heart or kidney conditions can affect which medicine is appropriate. Other glucose-lowering classes can be considered according to individual needs. Review risks, monitoring and the responsible prescriber before changing treatment.
Do you offer a GLP-1 program?
Medication options, including GLP-1 receptor agonists when appropriate, require an individual assessment of indication, risks, access and monitoring. Discuss the responsible prescriber, necessary tests and follow-up before changing treatment. Availability of a dedicated medication program or authorization service is not established by this page.
How often do I need an eye and foot exam?
Annually for both, per ADA Standards. The dilated retinal exam catches diabetic retinopathy — a leading cause of preventable blindness — before vision changes. The comprehensive foot exam uses monofilament testing for early peripheral neuropathy and a vascular check. Discuss who will perform eye and foot assessments, the appropriate interval, and any outside referral; onsite capacity and insurance participation require confirmation.
Does insurance cover diabetes visits and labs?
Confirm provider availability, test location, referrals, costs and insurance coverage before scheduling. Testing or specialist care may take place outside Viva; acceptance and timing require confirmation.
Will I need insulin?
Not all patients do. Many people manage type 2 diabetes for years with lifestyle plus non-insulin classes. Insulin is added when A1C remains above target despite combination therapy, in advanced disease, or in specific scenarios such as pregnancy, severe hyperglycemia at presentation, or hospitalization. If insulin is prescribed, agree on education, glucose monitoring, hypoglycemia safety and responsible follow-up.
Is bilingual diabetes education available?
Ask which English or Spanish visit and written education resources are available. Confirm remote care and portal support separately.
When should I be screened if I do not have symptoms?
The USPSTF 2021 recommendation supports screening for pre-diabetes and type 2 diabetes for adults 35-70 who are overweight or obese. The ADA recommends earlier and more frequent screening for higher-risk groups — Hispanic, Black, Asian American, and Native American adults, those with a family history, prior gestational diabetes, polycystic ovary syndrome, or cardiovascular disease. Test selection, collection location and result review should be confirmed for your assessment.